Immunologic parameters in histiocytosis-X
β Scribed by Sanford Leikin; Gregorio Puruganan; Anne Frankel; Ruth Steerman; Roma Chandra
- Publisher
- John Wiley and Sons
- Year
- 1973
- Tongue
- English
- Weight
- 602 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Twentyβfive children with generalized histiocytosis X were treated with a combination of cyclophosphamide, vinblastine, and prednisone: 8 patients experienced complete response, 8 partial response, 2 improvement, and 7 no response. Response rates for children over 1 year of age were hig
Twenty-eight patients with histiocytosis X (HX) who had bone marrow aspirates andlor trephine biopsies taken at diagnosis were studied. Five of the 28 patients (18%) had bone marrow specimens with clusters of benign histiocytes characteristic of histiocytosis X. Several statistically significant cli
Langerhans' cell histiocytosis (LCH) (previously histiocytosis X) is an infrequent disease with protean clinical manifestations and an unpredictable course. The role of radiotherapy in the soft tissue complications of LCH was evaluated in this retrospective study of 40 patients seen in two major Phi
Six children received etoposide as the single agent for treatment of Langerhans cell histiocytosis (LCH; histiocytosis X). Five were less than 2 years old at diagnosis. All had multiorgan involvement; one had liver and pulmonary dysfunction. Two infants also had clinical signs of immune deficiency.